Search
Cabozantinib Action Pathway
smpdb.ca/view/SMP0126903Drug actionCabozantinib's mechanism of action involves inhibiting various receptor tyrosine kinases, effectively suppressing processes such as metastasis, angiogenesis, and oncogenesis, making it a versatile therapeutic
Enzymes: Fibrinogen beta chain, Fibrinogen alpha chainNintedanib Action Pathway
smpdb.ca/view/SMP0126909Drug actionIt's indicated for idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease, and chronic fibrosing interstitial lung diseases with a progressive phenotype, where it
Enzymes: Fibrinogen beta chain, Fibrinogen alpha chainBrolucizumab Action Pathway
smpdb.ca/view/SMP0126913Drug actionIt functions as a vascular endothelial growth factor (VEGF) inhibitor, specifically targeting major VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). … Patients should be informed about potential risks, including endophthalmitis, retinal detachment, and arterial thromboembolic events, associated with this medication.
Enzymes: Fibrinogen beta chain, Fibrinogen alpha chainParnaparin Action Pathway
smpdb.ca/view/SMP0126175Drug actionIt can have interactions with food, it best to avoid herbs and supplements with anticoagulant and antiplatelet activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba. … It is usually administered subcutaneously and like other heparins has the risk of adverse effects such as deep vein thrombosis.
Drugs: CalciumEnzymes: Fibrinogen beta chain, Fibrinogen alpha chainEnoxaparin Prothrombin Anticoagulation Action Pathway
smpdb.ca/view/SMP0126448Drug actionEnoxaparin can interact with some herbs and supplements, avoid those with anticoagulant and antiplatelet activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba. … Enoxaparin is metabolized by the liver through depolymerization and desulfation to lower molecular weight metabolites. It is eliminated by the kidneys and generally has a half-life of 4 hours.
Enzymes: Fibrinogen beta chain, Fibrinogen alpha chainTirofiban Action Pathway (new)
smpdb.ca/view/SMP0126470Drug actionIt is administered intravenously and acts as an antagonist of the platelet glycoprotein IIb/IIIa receptor, this receptor is responsible for platelet aggregation in order to form a thrombus, without this
Enzymes: Fibrinogen alpha chain, Fibrinogen beta chainPegaptanib Action Pathway
smpdb.ca/view/SMP0126889Drug actionThis treatment approach is especially effective for patients with conditions like wet AMD, where VEGF-A levels are elevated and contribute to disease progression. … This polynucleotide aptamer is designed to bind to VEGF, reducing both angiogenesis and vessel permeability, particularly for neovascular age-related macular degeneration cases.
Enzymes: Fibrinogen beta chain, Fibrinogen alpha chainRamucirumab Action Pathway
smpdb.ca/view/SMP0126890Drug action, and migration of endothelial cells. … By binding to VEGFR2, ramucirumab disrupts the binding of ligands (VEGF-A, VEGF-C, and VEGF-D), thereby impeding receptor phosphorylation and downstream cellular responses like proliferation, permeability
Enzymes: Fibrinogen beta chain, Fibrinogen alpha chainPazopanib Action Pathway
smpdb.ca/view/SMP0126899Drug action, inhibited growth, and hypoxia in cancer cells. … for patients with advanced renal cell cancer and advanced soft tissue sarcoma.
Enzymes: Fibrinogen beta chain, Fibrinogen alpha chainLenvatinib Action Pathway
smpdb.ca/view/SMP0126908Drug actionroles in processes like angiogenesis, tumor growth, and cancer progression. … Lenvatinib also inhibits other RTKs, such as fibroblast growth factor receptors (FGFR1, 2, 3, and 4), the platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET, all of which play crucial
Enzymes: Fibrinogen beta chain, Fibrinogen alpha chain